MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q4
hinzugefügt 06.05.2026
NuCana plc Betriebsaufwand 2011-2026 | NCNA
Betriebsaufwand Jährlich NuCana plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 25.7 M | 22 M | 24 M | - | - | - | - | - | - |
Alle Zahlen in GBP-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 25.7 M | 22 M | 23.9 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
6.79 M | - | 1.35 % | $ 17.8 M |  China |
 |
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 7.14 | 1.56 % | $ 196 M |  Israel |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
BioNTech SE
BNTX
|
512 M | $ 93.13 | 1.07 % | $ 22.5 B | Germany |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M | Israel |
 |
Compugen Ltd.
CGEN
|
32.2 M | $ 2.71 | -3.16 % | $ 253 M | Israel |
 |
Abcam plc
ABCM
|
170 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
54 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
26.2 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
35.1 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
9.17 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
98.4 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
214 M | - | - | $ 3.37 B | China |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.68 | 4.04 % | $ 197 M | USA |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 14.64 | -1.61 % | $ 210 M | USA |
 |
Advaxis
ADXS
|
19.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
10.4 M | $ 3.46 | 1.74 % | $ 5.7 M | Israel |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
305 M | $ 21.02 | 0.77 % | $ 2.67 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
10.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |